Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373026 | 0.76 | ALDH1A1 (0.37) | ALDH1A1POLBF2PRSS1PRSS2 | |
| SCHEMBL6234104 | 0.74 | F2 (0.31) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5038355 | 0.74 | GLP1R (0.33) | F2 | |
| SCHEMBL6862733 | 0.74 | GLP1R (0.33) | F2 | |
| SCHEMBL18954623 | 0.74 | ALDH1A1 (0.38) | ALDH1A1POLBPKMGAAL3MBTL1 | |
| SCHEMBL18971864 | 0.73 | GNAI3 (0.38) | ALDH1A1POLBPKML3MBTL1 | |
| SCHEMBL18972003 | 0.73 | GNAI3 (0.38) | ALDH1A1POLBPKML3MBTL1 | |
| SCHEMBL6139797 | 0.73 | F2 (0.32) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5032641 | 0.71 | F2 (0.41) | ALDH1A1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL22273817 | 0.71 | GNAI3 (0.49) | ALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060093554-A1 | Galenical formulations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| EP-1307236-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2002013874-A2 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MR-IMAGING FOR THE REPRESENTATION OF PLAQUES, TUMOURS AND NECROSES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-21 | — | — | WO | disclosed |
| EP-1088558-A2 | Galenic formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | EPHX2 4456/4885NAMPT 4834/4885ALDH1A1 4799/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | EPHX2 4557/4885NAMPT 4825/4885ALDH1A1 4595/4885 |
| US-20060093554-A1 | Galenical formulations | GALC, GALR2, GALR1 | EPHX2 3872/4885NAMPT 2940/4885ALDH1A1 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.